Credit Suisee has entered into a strategic partnership with Israel-based health tech and life sciences specialist investment platform aMoon.
Through the partnership, Credit Suisse and Credit Suisse Asset Management will have the opportunity to present eligible Credit Suisse clients and institutional investors outside US and Canada access to $250m of investments into the aMoon II venture capital fund. This strategic venture was realised following the provisional closing of aMoon II at $200m from private investors in Israel on 1 April, 2018.
Yair Schindel, co-founder & managing partner of aMoon said. “This strategic partnership will leverage the growing convergence of technology and healthcare. Breakthrough scientific research, innovative technology, and decades of digital health records make Israel an ideal Launchpad for leading this global transformation in healthcare. This will generate deep value for our investors and positively impact the lives of millions of patients.”
Michel Degen, CEO of Credit Suisse Asset Management Switzerland and EMEA, added: “It is critical that, disruptive businesses, which are committed to resolving some of the healthcare sector’s most pressing issues, receive access to venture capital and the liquidity they need. We look forward to work with aMoon, a leader in health tech and life sciences investing.”